MYSummit Conference 2021
October 7-9, 2021, Edinburgh, UK
Radisson Blu Hotel
Eric Low Consultant MYELOMA360 Former CEO of Myeloma UK Edinburgh, UK
Eric has worked in the field of medical research charities for over 20 years. He founded Myeloma UK in 1996, leading the organisation as Chief Executive until 2017.
He currently runs a consultancy business specialising primarily in strategic market access, life sciences and healthcare policy, patient and patient group engagement.
Eric is committed and focused on improving patient outcomes and puts patients at the centre of everything he does. His goal is to have made a significant and material impact on the quality of life of patients and the prevention and curability of rare diseases. He has a strong track record of delivery and success in building multi-stakeholder research collaborations and consortia, and in delivering innovative solutions to complex issues, challenges and barriers standing in the way of progress.
Eric is also a Senior Visiting Research fellow at the University of Leeds Medical School, and he holds several Board, honorary, advisory and voluntary positions. He also advises numerous medical and health-focused charities on a pro bono basis. He was awarded an OBE for services to charity in the Queen’s Birthday Honours 2012.
Blake A. Morrison, PharmD
GLOBAL MEDICAL AND SCIENTIFIC AFFAIRS EXPERT
Blake Morrison brings over 30 years of clinical and industry experience with a therapeutic area emphasis on oncology and a focus on medical affairs, drug development, evidence generation, thought leader relationships and scientific communications.
Blake has amassed over 21 years direct experience in Multiple Myeloma, bringing specialized knowledge to this community. Blake has held leadership roles at Karyopharm, Onyx, Genentech, Sunesis and Millennium. Additionally, Blake has experience with the myeloma patient community, having served at the Multiple Myeloma Research Foundation in patient-focused data generating roles.
Blake graduated with his Doctor of Pharmacy from the University of the Pacific and completed residencies in infectious diseases and oncology.